19 documents found, page 1 of 2

Portuguese recommendations for the management of transthyretin amyloid cardiomy...

A Portuguese expert panel position paper on the management of heart failure wit...

Funding Information: Ana Santos of Prime Focus provided medical writing, editorial support, and formatting assistance, which was contracted and funded by Boehringer Ingelheim and Lilly Portugal. Publisher Copyright: © 2025; Heart failure (HF) with preserved ejection fraction (HFpEF) affects more than 50% of HF patients worldwide, and more than 70% of HF patients aged over 65. This is a complex syndrome with a c...

A Portuguese expert panel position paper on the management of heart failure wit...

Funding Information: Ana Santos of Prime Focus provided medical writing, editorial support, and formatting assistance, which was contracted and funded by Boehringer Ingelheim and Lilly Portugal. Publisher Copyright: © 2025; In Portugal, a 15.2% prevalence of heart failure with preserved ejection fraction (HFpEF) was recently identified among those aged ≥50 years. HFpEF represents 90% of Portuguese heart failure...

Correction to

Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2025.; The order of the authors' first and last names was reversed in the original publication. The correct author names are as follows: Incorrect Author List: Fonseca Cândida · Baptista Rui · Franco Fátima · Moura Brenda · Pimenta Joana · Pedro Moraes Sarmento · Silva Cardoso José · Br...

Beyond clinical trials – The cost saving associated with dapagliflozin use in P...

Publisher Copyright: © 2024 Sociedade Portuguesa de Cardiologia; Introduction and objectives: Heart failure (HF) is a clinical syndrome associated with substantial morbidity, mortality, and healthcare costs. Dapagliflozin has proven efficacy in reducing the risk of death and hospitalization in HF patients, regardless of left ventricular ejection fraction (LVEF). This paper aimed to project the potential impact ...

Perspetivas de peritos sobre fatores estratégicos para a gestão e prevenção da ...

Publisher Copyright: © 2023 Sociedade Portuguesa de Cardiologia; Introduction and objectives: Heart failure (HF) has significant morbidity and mortality, and its prevalence will continue to increase in the future. This unfavorable evolution requires reflection as well as recommendations and decisions based on expert critical and strategic appraisal. Methods: In the Acceleration on Heart Failure Empowerment and ...

Estudo de Prevalência de Insuficiência Cardíaca em Portugal (PORTHOS), fundamen...

Funding Information: PORTHOS study arises from a scientific partnership between the Portuguese Society of Cardiology, AstraZeneca and NOVA Medical School. The authors are especially grateful to all the institutional partners that collaborated at various levels: Associação de Apoio aos Doentes com Insuficiência Cardíaca (AADIC), GlobalSports, Maria Design, Missão Continente (Sonae), Unilabs and GE. For the colla...

NT-proBNP no diagnóstico de insuficiência cardíaca nos cuidados de saúde primários

Funding Information: This study was supported by Roche Diagnostics. The authors had full control of the content and made the final decision on all aspects of this article. Publisher Copyright: © 2021 Sociedade Portuguesa de Cardiologia; Introduction and objectives: Chronic heart failure (CHF) is a growing public health concern and diagnosis can be challenging, particularly in primary care. This study aims to es...

Management of RAASi-associated hyperkalemia in patients with cardiovascular dis...

Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). However, RAASi may induce hyperkalemia, a potentially life-threatening disorder. This risk is further increased in those with concomitant chronic kidney disease, diabetes m...

Otimização do tratamento da insuficiência cardíaca com fração de ejeção reduzid...

Funding Information: Medical writer Duarte Oliveira (W4Research) collaborated in the preparation of this article, with financial support from Novartis Portugal. This article contains the authors? opinion on the scientific contents addressed, which are expressed independently of Novartis. Novartis did not participate in the design, discussion of, or writing of this paper. Funding Information: Medical writer Duar...